HORDB

ID: hd00022
Active Ingredients: Pramlintide
DRUGBANK Accession Number: DB01278
Active Sequence: KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY
Sequence Length: 37
Type: Biotech
Description: Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Disease: Type 1 and type 2 diabetes
CAS: 151126-32-8
SMILES: CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N

Drug Name	Strength	Dosage Form/Route	Company	Marketing Status	Approval year
SYMLIN	EQ 3MG BASE/5ML(EQ 600MCG BASE/ML); EQ 1.5MG BASE/1.5ML(EQ 1MG BASE/ML); EQ 2.7MG BASE/2.7ML(EQ 1MG BASE/ML)	INJECTABLE; SUBCUTANEOUS	ASTRAZENECA AB	Discontinued(EQ 3MG BASE/5ML (EQ 600MCG BASE/ML));Prescription(EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)&EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML))	2005